Keyword: Foundation Medicine
Merck paired up with Foundation Medicine to develop a pan-cancer diagnostic for Keytruda to measure microsatellite instability and other biomarkers.
Bristol-Myers Squibb and Flatiron Health signed a three-year agreement, planning to form an advisory board on real-world evidence in drug submissions.
The alliance will see Foundation Medicine use pan-cancer test FoundationOne CDx as a companion diagnostic for Pfizer drugs.
The past week's research news included developments in pediatric brain tumors, asthma and KRAS-mutant cancers.
Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition.
Gritstone Oncology has appointed Raphaël Rousseau, M.D., Ph.D., as its CMO.
Eisai’s spinoff unit H3 Biomedicine has expanded its 2015 deal with Foundation Medicine as the pair look for new cancer drivers.